1. Home
  2. SD vs ERAS Comparison

SD vs ERAS Comparison

Compare SD & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SD
  • ERAS
  • Stock Information
  • Founded
  • SD 2006
  • ERAS 2018
  • Country
  • SD United States
  • ERAS United States
  • Employees
  • SD N/A
  • ERAS N/A
  • Industry
  • SD Oil & Gas Production
  • ERAS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SD Energy
  • ERAS Health Care
  • Exchange
  • SD Nasdaq
  • ERAS Nasdaq
  • Market Cap
  • SD 437.0M
  • ERAS 439.7M
  • IPO Year
  • SD 2007
  • ERAS 2021
  • Fundamental
  • Price
  • SD $12.05
  • ERAS $2.43
  • Analyst Decision
  • SD
  • ERAS Buy
  • Analyst Count
  • SD 0
  • ERAS 6
  • Target Price
  • SD N/A
  • ERAS $3.83
  • AVG Volume (30 Days)
  • SD 323.0K
  • ERAS 2.3M
  • Earning Date
  • SD 11-05-2025
  • ERAS 11-11-2025
  • Dividend Yield
  • SD 3.98%
  • ERAS N/A
  • EPS Growth
  • SD 86.17
  • ERAS N/A
  • EPS
  • SD 2.03
  • ERAS N/A
  • Revenue
  • SD $146,165,000.00
  • ERAS N/A
  • Revenue This Year
  • SD $30.71
  • ERAS N/A
  • Revenue Next Year
  • SD $10.06
  • ERAS N/A
  • P/E Ratio
  • SD $5.94
  • ERAS N/A
  • Revenue Growth
  • SD 13.89
  • ERAS N/A
  • 52 Week Low
  • SD $8.81
  • ERAS $1.01
  • 52 Week High
  • SD $13.00
  • ERAS $3.31
  • Technical
  • Relative Strength Index (RSI)
  • SD 59.17
  • ERAS 73.25
  • Support Level
  • SD $12.01
  • ERAS $2.21
  • Resistance Level
  • SD $13.00
  • ERAS $2.65
  • Average True Range (ATR)
  • SD 0.37
  • ERAS 0.21
  • MACD
  • SD 0.06
  • ERAS 0.06
  • Stochastic Oscillator
  • SD 54.21
  • ERAS 89.39

About SD SandRidge Energy Inc.

SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: